Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

559 ARTÍCULOS , VIENDO DEL 1 AL 15

The Current Evidence for the Therapeutic Role of Curcumin in Alzheimer's Disease

Bland AR, Ashton JC, Kamal MA, Sahebkar A.

CNS Neurol Disord Drug Targets. 2023;22(3):318-320. doi: 10.2174/1871527321666220119105836.

Impact of the Cannabinoid System in Alzheimer's Disease

Li S, Huang Y, Yu L, Ji X, Wu J.

Curr Neuropharmacol. 2023;21(3):715-726. doi: 10.2174/1570159X20666220201091006.

Selenium-Derivative Compounds: A Review of New Perspectives in the Treatment of Alzheimer's Disease

Barbosa FAR, Canto RFS, Teixeira KF, de Souza AS, de Oliveira AS, Braga AL.

Curr Med Chem. 2023;30(6):689-700. doi: 10.2174/0929867329666220224161454.

Epigenetic Modifications by Estrogen and Androgen in Alzheimer's Disease

Kumar R, Fatima F, Yadav G, Singh S, Haldar S, Alexiou A, Ashraf GM.

CNS Neurol Disord Drug Targets. 2023;22(1):6-17. doi: 10.2174/1871527321666220225110501.

Role of Oxysterols in the Activation of the NLRP3 Inflammasome as a Potential Pharmacological Approach in Alzheimer's Disease

Martins GL, Ferreira CN, Palotás A, Rocha NP, Reis HJ.

Curr Neuropharmacol. 2023;21(2):202-212. doi: 10.2174/1570159X20666220327215245.

Nanotechnology: A Promising Targeted Drug Delivery System for Brain Tumours and Alzheimer's Disease

Unnisa A, Greig NH, Kamal MA.

Curr Med Chem. 2023;30(3):255-270. doi: 10.2174/0929867329666220328125206.

Current Drug Targets in Alzheimer's Associated Memory Impairment: A Comprehensive Review

Mathew A, Balaji E V, Pai SRK, Kishore A, Pai V, Pemmireddy R, K S C.

CNS Neurol Disord Drug Targets. 2023;22(2):255-275. doi: 10.2174/1871527321666220401124719.

Therapeutic Effects of Thymoquinone on Alzheimer's Disease through Modulating Amyloid-beta Neurotoxicity and Neuro-inflammatory Cytokine Levels

Alasmari F, Alotaibi FM, Al-Qahtani WS, AlAsmari AF, Alqahtani F.

CNS Neurol Disord Drug Targets. 2023;22(5):736-744. doi: 10.2174/1871527321666220418125057.

Berberine: Is it a Promising Agent for Mental Disorders Treatment?

Shayganfard M.

Curr Mol Pharmacol. 2023;16(3):307-320. doi: 10.2174/1874467215666220509213122.

The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease

Ravikumar M, Mohan S, Velpandian C.

Curr Drug Saf. 2023;18(3):284-296. doi: 10.2174/1574886317666220517125644.

Anti-Amyloid-β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease

Sharma P, Babbar R, Sharma T, Madaan P, Arora S, Badavath VN.

Mini Rev Med Chem. 2023;23(1):53-66. doi: 10.2174/1389557522666220524090354.

DYRK1A Inhibitors and Perspectives for the Treatment of Alzheimer's Disease

de Souza MM, Cenci AR, Teixeira KF, Machado V, Mendes Schuler MCG, Gonçalves AE, Paula Dalmagro A, André Cazarin C, Gomes Ferreira LL, de Oliveira AS, Andricopulo AD.

Curr Med Chem. 2023;30(6):669-688. doi: 10.2174/0929867329666220620162018.

Anticholinesterase Agents For Alzheimer's Disease Treatment: An Updated Overview

Llanes LC, Kuehlewein I, França IV, da Silva LV, da Cruz Junior JW.

Curr Med Chem. 2023;30(6):701-724. doi: 10.2174/0929867329666220803113411.

The Molecular and Functional Changes of Neural Stem Cells in Alzheimer's Disease: Can They be Reinvigorated to Conduct Neurogenesis

Abu-El-Rub E, Khasawneh RR, Almahasneh FA, Aloud BM, Zegallai HM.

Curr Stem Cell Res Ther. 2023;18(5):580-594. doi: 10.2174/1574888X17666220831105257.

Genetic Causes of Alzheimer's Disease and the Neuroprotective Role of Melatonin in its Management

Sundram S, Malviya R, Awasthi R.

CNS Neurol Disord Drug Targets. 2023;22(9):1302-1312. doi: 10.2174/1871527321666220901125730.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias